A phase II baseline versus treatment study to determine the efficacy of raltegravir (ISENTRESS) in preventing progression of relapsing remitting multiple sclerosis as determined by gadolinium-enhanced MRI

Metadata

Published
2013-08-22
DOI
  • 10.1186/isrctn82487767
Publisher
Springer Science and Business Media LLC
Creator Name (e-Rad)
  • Ailsa Weatherall

Related Articles

See more

Details 詳細情報について

Back to top